Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results